Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of rheumatoid arthritis (RA) ≥ 3 months.~* Moderately to severely active rheumatoid arthritis.~* Participants who per investigator judgment were incomplete responders to at least 12 weeks of an adequate dose of continuous treatment with or who were intolerant of one or a combination of non-biologic disease modifying anti-rheumatic drugs (DMARDs).~Exclusion criteria:~* Participants \< 18 years of age.~* Past history of, or current, autoimmune or inflammatory systemic or localized joint disease(s) other than RA.~* History of juvenile idiopathic arthritis or arthritis onset prior to age 16.~* Severe active systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome.~* Prior treatment with any biologic anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies.~* Treatment with prednisone \> 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization.~* New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors within 4 weeks prior to randomization, except for the use of low-dose acetylsalicylic acid for cardiovascular diseases.~* Use of parenteral glucocorticoids or intra-articular glucocorticoids injection within 4 weeks prior to randomization.~* Prior treatment with a Janus kinase (JAK) inhibitor (tofacitinib).~* New treatment or dose-adjustment to on-going medication for dyslipidemia, such as statin, within 6 weeks prior to randomization.~* Participation in any clinical research study evaluating another investigational drug or therapy within 5 half-lives or 60 days of first dose of study drug administration, whichever is longer.~* Participants with a history of malignancy other than adequately-treated carcinoma in-situ of the cervix, non-metastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization visit. Non-malignant lymphoproliferative disorders are also excluded.~* Participants with active tuberculosis or untreated latent tuberculosis infection.~* Pregnant or breast feeding women.~The above information is not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarilumab 150 mg q2w (Type: EXPERIMENTAL): Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
- Sarilumab 200 mg q2w (Type: EXPERIMENTAL): Sarilumab 200 mg SC injection q2w for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).